Program highlights

The Biomedical Translation Fund

The $500 million Biomedical Translation Fund (BTF), the first investment from the MRFF, will stimulate private sector investment in biomedical commercialisation and create additional opportunities for foreign investors to access Australia’s expertise and discoveries.

Fund managers Brandon Capital Partners, OneVentures Management and BioScience Managers were announced in 2016. They will bring at least matching funding from the private sector for investment, helping investors access greater value for their investment by leveraging the public contribution.

Plenary presentation: Prof Peter Choong

The concept of harnessing the power of science and technology to deliver personalised medical solutions for trauma, tumour, degeneration and disease has become an irresistible quest that has galvanised scientists and clinicians.

Today’s researchers are equipped with tools to improve quality of life, repair and regenerate sensory and motor systems and find ways to emulate the body’s “vital” organs.

In his plenary presentation, Prof Peter Choong asks what these rapid advances in information technology, computational science and advanced manufacturing will mean for the future. He says these technologies offer hope for the return of hearing, sight, touch, movement and independence.

Prof Choong is the Sir Hugh Devine Professor of Surgery, University of Melbourne, and Director of Orthopaedics, St. Vincent’s Hospital Melbourne. He will deliver a plenary presentation, We are such stuff as dreams are made on, on the first day of AusMedtech 2017 & ICMMB 2017.



Cloud-based solutions with Jenny O’Neill, CEO, Episoft

Hear Episoft CEO Jenny O’Neill, with over 25 years’ experience in the health ICT sector, discuss the challenges of developing technologies that enable common workflows and data capture.

With enormous changes in the availability and take-up of technology by hospitals and community based health providers, there is a growing trend to develop technologies that support clinical care and support lower cost research platforms. These technologies can be used in a range of settings, including simple clinical audits and entire hospital systems. They support efforts to reduce the burden of disease cost, with cancer and mental among the most serious chronic illnesses targeted.

Despite the benefits of these emerging technologies, Ms O’Neill says there are challenges in securing the investment.

“With an investment community that is nascent when it comes to early stage business growth in a complex marketplace and a mere five per cent of capital going to female-led businesses, the odds of attracting investment to grow an eHealth business remain stacked against us. In such a tough business climate, what motivates us to keep going is that we are about improving today’s treatments and informing tomorrow’s cures,” says Ms O’Neill.

Ms O’Neill will speak in the Emerging Technologies session on the first day of AusMedtech 2017 & ICMMB 2017.



How a surgical researcher broke the skin barrier with Dr Gil Stynes

Many medical devices, such as intravenous lines, catheters, and robotics, need to pass through skin. All are plagued by infection at the interface with skin. In particular, robotic developments are held back by problems at the skin interface.

Dr Gil Stynes has pioneered technology that gets skin to attach to skin-penetrating devices, reducing the risk of infection and opening the possibility of long-term implantation.

Dr Stynes will speak in the Emerging Technologies session, to be held on the first day of AusMedtech 2017 & ICMMB 2017.

Read more from the University of Melbourne.

Tweets by @AusBiotech


Host State Partner